| Identification | Back Directory | [Name]
WKYMVM | [CAS]
187986-17-0 | [Synonyms]
WKYMVM
WKYMVMaMide, W-Peptide
Trp-Lys-Tyr-Met-Val-D-Met
M.W. 856.11 C41H61N9O7S2
WKYMVMAMIDE TRIFLUOROACETATE
WKYMVdM trifluoroacetate salt
H-Trp-Lys-Tyr-Met-Val-D-Met-NH2
H-TRP-LYS-TYR-MET-VAL-D-MET-NH2 TRIFLUOROACETATE
H-Ala-Val-Thr-Tyr-Ser-Arg-Ser-Arg-Tyr-Leu-Glu-Cys-OH
Urokinase PlasMinogen Activator Receptor (84-95) (huMan)
Tryptophanyl-lysinyl-tyrosinyl-methionyl-valinyl-D-methionine
D-Methioninamide, L-tryptophyl-L-lysyl-L-tyrosyl-L-methionyl-L-valyl-
Trp-Lys-Tyr-Met-Val-D-Met NH2 trifluoroacetate salt trifluoroacetate salt | [Molecular Formula]
C41H61N9O7S2 | [MDL Number]
MFCD04974480 | [MOL File]
187986-17-0.mol | [Molecular Weight]
856.11 |
| Chemical Properties | Back Directory | [Boiling point ]
1269.6±65.0 °C(Predicted) | [density ]
1.268±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
H2O: >2mg/mL | [form ]
powder | [pka]
9.82±0.15(Predicted) | [color ]
white to off-white | [Water Solubility ]
Soluble to 2 mg/ml in water | [Sequence]
Trp-Lys-Tyr-Met-Val-{d-Met}-NH2 |
| Hazard Information | Back Directory | [Uses]
WKYMVm is a lipoxin A4 receptor and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. | [in vivo]
WKYMVm (4 mg/kg; Intraperitoneal injection; 3 times; 24 h interval) has a protective effect in rat spinal cord injury model[3].
WKYMVm (2.5 mg/kg; Intraperitoneal injection; 4 days) can alleviate hyperoxy-induced lung injury in neonatal mice[4].
WKYMVm (8 mg/kg; Subcutaneous injection; Once every two days; 2-5 weeks) improves obesity in high-fat fed mouse models[5]. | Animal Model: | Adult female Sprague-Dawley rats (200-220 g) with spinal cord injury[3] | | Dosage: | 4 mg/kg | | Administration: | Intraperitoneal injection (i.p.); 3 times with 24 hours intervals | | Result: | Reduce structural disorders and neuronal loss.
Reduced the phosphorylation of ERK1/2 and NF-κB p65 but not p38.
|
| Animal Model: | Normoxia or hyperoxic treated newborn mouse pups of C57/BL6[4] | | Dosage: | 2.5 mg/kg | | Administration: | Intraperitoneal injection (i.p.); daily from postnatal day (P) 5 to P8. | | Result: | Significantly attenuated hyperoxia-induced lung inflammation, as evidenced by increased inflammatory cytokines, neutrophils, and alveolar macrophages, and resultant lung injuries, which included impaired alveolarization and angiogenesis, an increased number of apoptotic cells, and reduced levels of growth factors in vivo, such as vascular endothelial growth factor and hepatocyte growth factor. |
| Animal Model: | High fat diet treated male wild-type C57BL/6N mice aged 8 weeks old (21?±?2?g)[5] | | Dosage: | 8?mg/kg | | Administration: | Subcutaneous injection (i.h.); once every 2?days; 2 or 5 weeks | | Result: | Significantly attenuated body weight gain, food intake and increased insulin sensitivity.
Markedly ameliorated HFD-induced hepatic steatosis and adipose tissue hypertrophy.
Improved lipid metabolism in adipose tissue.
Improved leptin signalling in the hypothalamus.
|
| [storage]
Store at -20°C |
|
|